It is worth noting that the use of selective β3-AR agonists comes with challenges as some of the β3-AR agonists have been approved to treat overactive bladder and urinary incontinence (20–22), but none of them have been approved to treat metabolic diseases. This evidence concerns the gene ADRB3 and Other metabolic disease.